YM-155 Hydrochloride: Benchmark Survivin Inhibitor for Cancer Research

Executive Summary: YM-155 hydrochloride is a highly potent small-molecule survivin inhibitor (IC₅₀ = 0.54 nM) widely utilized in apoptosis and oncology research (product source). It demonstrates robust selectivity for survivin with negligible activity against other inhibitor of apoptosis proteins (IAPs) or BCL-2 family members (Schwartz 2022). YM-155 effectively induces tumor regression across multiple xenograft models and cell lines, including non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) (Schwartz 2022). The compound is well-characterized in terms of solubility, stability, and storage requirements, ensuring reproducibility in laboratory workflows. Recent literature and product documentation confirm its continued relevance and reliability in preclinical cancer drug evaluation (survivin.net).

Biological Rationale

Survivin is a member of the inhibitor of apoptosis (IAP) gene family. It is the smallest IAP but plays a critical role in cancer cell survival and proliferation. Survivin is overexpressed in many human tumors but is minimally expressed in most normal adult tissues (Schwartz 2022). This differential expression makes survivin an attractive therapeutic target in oncology. Inhibiting survivin disrupts cell division and promotes apoptosis, reducing tumor growth and resistance to therapy (survivin.net). Targeting the survivin signaling pathway is thus a validated strategy for cancer drug discovery and evaluation.

Mechanism of Action of YM-155 hydrochloride

YM-155 hydrochloride is a small-molecule survivin suppressant. It binds to the survivin promoter and downregulates survivin expression at the transcriptional level. This selectivity results in decreased survivin protein levels without significantly affecting other IAPs or the BCL-2 family (Schwartz 2022). The compound’s IC₅₀ for survivin inhibition is 0.54 nM in cell-based assays. By suppressing survivin, YM-155 induces mitotic arrest, increases caspase activation, and promotes apoptotic cell death in cancer cells. This mechanism underpins its anti-proliferative and pro-apoptotic effects across a wide range of tumor models. For a complete overview of molecular mechanisms and workflows, see the extended discussion at survivin.net, which this article updates with new parameter guidance.

Evidence & Benchmarks

• YM-155 hydrochloride inhibits survivin expression in vitro with an IC₅₀ of 0.54 nM in cancer cell lines (Schwartz 2022, Table 2.1).
• YM-155 shows minimal off-target effects on other IAPs and BCL-2 proteins at concentrations up to 1 μM (Schwartz 2022, Fig. 2.3).
• In xenograft models, YM-155 induces regression in NSCLC, melanoma, bladder, aggressive non-Hodgkin lymphoma, and breast cancer tumors (Schwartz 2022, Chapter 3).
• YM-155 reduces spontaneous metastases and prolongs overall survival in animal models with metastatic TNBC cell lines (Schwartz 2022, Table 4.2).
• Solubility is ≥19.45 mg/mL in DMSO, ≥4.34 mg/mL in ethanol (with gentle warming and ultrasonic treatment), and ≥48.1 mg/mL in water (with ultrasonic treatment); optimal storage is at -20°C (ApexBio).

Applications, Limits & Misconceptions

YM-155 hydrochloride is extensively applied for the study of apoptosis mechanisms, drug screening, and evaluation of anti-cancer therapeutics. It is a benchmark tool for dissecting survivin-driven pathways in both in vitro and in vivo models. The compound is not suitable for diagnostic or clinical use and is intended solely for research purposes. While highly selective, its effects are context-dependent and may vary with cell line, tumor type, and experimental design.

Common Pitfalls or Misconceptions

• YM-155 does not inhibit all IAPs or BCL-2 family proteins; its selectivity is primarily for survivin (Schwartz 2022).
• It is not stable in solution for extended periods; fresh preparations are recommended (ApexBio).
• YM-155 is not approved for clinical or diagnostic applications; use is restricted to laboratory research.
• Anti-tumor efficacy in animal models may not directly translate to clinical outcomes in humans (Schwartz 2022).
• Cellular responses can be variable based on genetic background and experimental conditions.

Workflow Integration & Parameters

YM-155 hydrochloride (SKU: A3947) is provided as a solid. For optimal solubility, dissolve at ≥19.45 mg/mL in DMSO, or ≥4.34 mg/mL in ethanol with gentle warming and ultrasonic treatment. Water solubility is ≥48.1 mg/mL with ultrasonic treatment. Store at -20°C and prepare solutions fresh for each experiment to ensure compound integrity (ApexBio). Use in proliferation and apoptosis assays should follow cell line-specific optimization. For direct comparisons and further protocol guidance, see the related article "YM-155 Hydrochloride: Potent Survivin Inhibitor for Cancer…", which this dossier clarifies by providing updated solubility and storage recommendations.

Conclusion & Outlook

YM-155 hydrochloride remains a reference standard for studying the survivin signaling pathway and apoptosis inhibition in cancer research. Its high selectivity, reproducible performance, and well-documented parameters make it indispensable for preclinical studies. Future research may expand on survivin-targeted strategies and explore combinations with other pathway inhibitors. For further details or to obtain YM-155 hydrochloride, consult the A3947 product page. This article updates and extends the mechanistic and protocol discussions found in previous reviews, ensuring current best practices are applied (survivin.net).